| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Warfarin Sodium | Coufatex | 4.5. Interactions with other medicinal products | Interactions with Ibrutinib. | Nov,2023 |
| Dabigatran Etexilate Mesylate | Pradaxa | 4.8. Undesirable effects | Anticoagulant-related nephropathy in patients with predisposing risk factors | May,2024 |
| Voriconazole | Vfend | 4.8 Undesirable effects | Phototoxicity and Periostitis (Update the frequency) | Nov,2023 |
| Larotrectinib | Vitrakvi | 4.8 Undesirable effects | Hepatotoxicity | Nov,2023 |
| Ibrutinib | Imbruvica | 4.8 Undesirable effects | Pyogenic granuloma and Acute kidney injury | Nov,2023 |
| Tadalafil | Cialis | 4.4 Special Warnings and Special Precautions for Use | Central Serous Chorioretinopathy | Nov,2023 |